BioWorld

April 29, 2002

FDA Nixes Cellegy Pain Drug; Stock Takes Half-Off Nosedive

Cellegy Pharmaceuticals Inc.’s stock tumbled more than 50 percent on news that the company is withdrawing the new drug application for Cellegesic, its nitroglycerin ointment for the treatment of pain from anal fissures. (BioWorld Today) Read More

Senators Want To Close Gaps In Generic Drug Legislation

Hirschsprung Disease Gene Find Is First Complete Dissection Of Multifactorial Genetic Disorder

IDEC, Seikagaku Add $34M Extension To IDEC-152 Deal

Other News To Note

BIO Names Specter, Harkin Top Legislators Of The Year

Appointments And Advancements

Quarterly Earnings Reports

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...